Clinical trial of the neoadjuvant standard chemotherapy 3 FEC [fluorouracil + epirubicin + cyclophosphamide] 100 + 3 Taxotere [docetaxel] protocol versus the same protocol adapted as a function of clinical response
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2014
At a glance
- Drugs Docetaxel (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil
- Indications Early breast cancer
- Focus Therapeutic Use
- 30 Sep 2014 Status changed from recruiting to completed as per ClinicalTrials.gov record
- 27 Sep 2011 Interim results presented at the 2011 European Multidisciplinary Cancer Congress.
- 07 Jun 2011 Interim results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.